Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial.
J Int Med Res. 2018 Jan; 46(1):326-334.JI

Abstract

Objective To evaluate the efficacy and safety of adalimumab (ADA) versus hyaluronic acid (HA) by intra-articular injection for moderate to severe knee osteoarthritis. Methods Fifty-six consecutive patients with moderate to severe knee osteoarthritis were randomly allocated to either the ADA group or HA group. On day 0, patients in the ADA group received 10 mg of ADA by intra-articular injection, while those in the HA group received 25 mg of HA. All patients received celecoxib at 200 mg/day for 4 weeks. The pain visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Patient Global Assessment (PGA), and Physician Global Assessment (PhGA) scores were assessed. Results At baseline, the pain VAS, WOMAC, PGA, and PhGA scores were similar between the two groups. The decrease in the pain VAS score, WOMAC pain score, WOMAC physical function score, and WOMAC total score from baseline to week 4 were greater in the ADA than HA group. A greater decrease in the PGA and PhGA scores from baseline to week 4 was noted in the ADA than HA group. No difference in adverse events was observed between the two groups. Conclusion ADA by intra-articular injection was effective and tolerated for moderate to severe knee osteoarthritis.

Authors+Show Affiliations

Department of Orthopedics, ZhongNan Hospital of Wuhan University, Wuhan, China.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

28840750

Citation

Wang, Jianping. "Efficacy and Safety of Adalimumab By Intra-articular Injection for Moderate to Severe Knee Osteoarthritis: an Open-label Randomized Controlled Trial." The Journal of International Medical Research, vol. 46, no. 1, 2018, pp. 326-334.
Wang J. Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. J Int Med Res. 2018;46(1):326-334.
Wang, J. (2018). Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. The Journal of International Medical Research, 46(1), 326-334. https://doi.org/10.1177/0300060517723182
Wang J. Efficacy and Safety of Adalimumab By Intra-articular Injection for Moderate to Severe Knee Osteoarthritis: an Open-label Randomized Controlled Trial. J Int Med Res. 2018;46(1):326-334. PubMed PMID: 28840750.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. A1 - Wang,Jianping, Y1 - 2017/08/25/ PY - 2017/8/26/pubmed PY - 2018/8/2/medline PY - 2017/8/26/entrez KW - Efficacy KW - adalimumab KW - hyaluronic acid KW - intra-articular KW - knee osteoarthritis KW - safety SP - 326 EP - 334 JF - The Journal of international medical research JO - J. Int. Med. Res. VL - 46 IS - 1 N2 - Objective To evaluate the efficacy and safety of adalimumab (ADA) versus hyaluronic acid (HA) by intra-articular injection for moderate to severe knee osteoarthritis. Methods Fifty-six consecutive patients with moderate to severe knee osteoarthritis were randomly allocated to either the ADA group or HA group. On day 0, patients in the ADA group received 10 mg of ADA by intra-articular injection, while those in the HA group received 25 mg of HA. All patients received celecoxib at 200 mg/day for 4 weeks. The pain visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Patient Global Assessment (PGA), and Physician Global Assessment (PhGA) scores were assessed. Results At baseline, the pain VAS, WOMAC, PGA, and PhGA scores were similar between the two groups. The decrease in the pain VAS score, WOMAC pain score, WOMAC physical function score, and WOMAC total score from baseline to week 4 were greater in the ADA than HA group. A greater decrease in the PGA and PhGA scores from baseline to week 4 was noted in the ADA than HA group. No difference in adverse events was observed between the two groups. Conclusion ADA by intra-articular injection was effective and tolerated for moderate to severe knee osteoarthritis. SN - 1473-2300 UR - https://www.unboundmedicine.com/medline/citation/28840750/Efficacy_and_safety_of_adalimumab_by_intra_articular_injection_for_moderate_to_severe_knee_osteoarthritis:_An_open_label_randomized_controlled_trial_ L2 - http://journals.sagepub.com/doi/full/10.1177/0300060517723182?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -